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Bone marrow-derived mesenchymal stem
cells promote colorectal cancer progression
via CCR5
Gen Nishikawa1, Kenji Kawada1, Jun Nakagawa1, Kosuke Toda1, Ryotaro Ogawa1, Susumu Inamoto1, Rei Mizuno1,
Yoshiro Itatani1 and Yoshiharu Sakai1
Abstract
Mesenchymal stem cells (MSCs) are recruited from BM to the stroma of developing tumors, where they serve as critical
components of the tumor microenvironment by secreting growth factors, cytokines, and chemokines. The role of
MSCs in colorectal cancer (CRC) progression was controversial. In this study, we found that C-C chemokine receptor
type 5 (CCR5) ligands (i.e., C-C motif chemokine ligand 3 (CCL3), CCL4, and CCL5) were highly produced from MSCs
using a chemokine array screening with conditioned media from the cultured human MSCs. A relatively strong CCR5
expression could be detected within the cytoplasm of several CRC cell lines. Regarding the effect of MSC, we found
that the xenografts in which CCR5-overexpressing HCT116 cells were inoculated into immunocompromised mice
were highly promoted in vivo by a mixture with MSCs. Notably, the CCR5 inhibitor, maraviroc, signiﬁcantly abolished
the MSC-induced tumor growth in vivo. In human clinical specimens (n= 89), 20 cases (29%) were high for CCR5,
whereas 69 cases (71%) were low. Statistical analyses indicated that CCR5 expression in primary CRC was associated
with CRC patients’ prognosis. Especially, stage III/IV patients with CCR5-high CRCs exhibited a signiﬁcantly poorer
prognosis than those with CCR5-low CRCs. Furthermore, we investigated the effects of preoperative serum CCR5
ligands on patients’ prognosis (n= 114), and found that CRC patients with high serum levels of CCL3 and CCL4
exhibited a poorer prognosis compared to those with low levels of CCL3 and CCL4, while there was no association
between CCL5 and prognosis. These results suggest that the inhibition of MSC–CRC interaction by a CCR5 inhibitor
could provide the possibility of a novel therapeutic strategy for CRC, and that serum levels of CCL3 and CCL4 could be
predictive biomarkers for the prognosis of CRC patients.
Introduction
Colorectal cancer (CRC) is the third most common
cancer and the fourth most common cause of cancer
death worldwide, accounting for about 1.36 million deaths
every year1. If it remains localized, the 5-year survival rate
is about 90%. When it spreads to lymph nodes and distant
organs, the 5-year survival rate reduces to about 70% and
to about 10%, respectively2. There is mounting evidence
that the tumor–stromal interaction, so-called tumor
microenvironment (TME), promotes tumor invasion and
metastasis through chemokine signaling3. The tumor
stroma contains extracellular matrix and several types of
host cells, including immune cells, vascular cells, and
mesenchymal cells. The molecular mechanisms involved
in the recruitment of these stromal cells to the tumor are
poorly understood.
Mesenchymal stem cells (MSCs) were ﬁrst discovered in
bone marrow (BM) stroma in the 1960s4, and are plur-
ipotent progenitor cells that contribute to the normal
homeostasis and remodeling following injury in a variety
of tissues5. Although MSCs reside predominantly in the
BM, they can be distributed throughout the body. MSCs
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display some properties, such as the tendency to home
into the sites of injury, capacity to suppress immune
reactions, and promote the repair of damaged tissues. Due
to these properties, MSCs have been explored for their
application as cell sources in regenerative medicine and as
delivery vehicles in gene therapy5. Growing tumors are
considered as “chronic wounds that do not heal6”, and can
activate the recruitment of host cells to promote pro-
liferation and survival of tumor cells. In the context of
cancer, recent studies have proposed that MSCs are
recruited from BM to the stroma of developing tumors,
where they serve as critical components of the TME. For
example, Karnoub et al. reported that when breast cancer
cells were mixed with MSCs and injected subcutaneously,
lung metastasis was accelerated through the CCL5–CCR5
axis in the experimental mouse models7. Some chemo-
kines and cytokines have been reported to be involved in
the interaction between MSCs and cancers8,9.
In the present study, we investigated the interaction
between CRC cells and MSCs, focusing on the chemokine
signaling. We demonstrated that human MSCs secreted
high levels of CCR5 ligands (i.e., CCL3, CCL4, and CCL5),
and that MSCs promoted CRC tumor growth in vivo via
CCR5 signaling. The xenografts in which CCR5-
overexpressing CRC cells were inoculated into immuno-
compromised mice were highly promoted by a mixture
with MSCs. Notably, we found that the CCR5 inhibitor,
maraviroc, abolished the MSC-induced tumor growth
in vivo. In human clinical specimens, we found that CCR5
expression in primary CRC was associated with CRC
patients’ prognosis. Especially, stage III/IV patients with
CCR5-high CRCs exhibited a signiﬁcantly poorer prog-
nosis than those with CCR5-low CRCs. We further
showed that CRC patients with high serum levels of CCL3
and CCL4 exhibited a poorer prognosis compared to
those with low levels of CCL3 and CCL4. These results
suggest that a CCR5 inhibitor may provide the possibility
of a novel therapeutic strategy for CRC, and that serum
levels of CCL3 and CCL4 could be predictive biomarkers
for the prognosis of CRC patients.
Results
CCL3/4/5–CCR5 axis is a candidate that functions between
MSCs and CRC cells, which resulted in tumor growth in vivo
Based on the previous reports that have shown that
MSCs promote tumor progression in several types of
cancer including breast cancer7,10, prostate cancer11,12,
and gastric cancer13–15, we hypothesized that the che-
mokine crosstalk between MSCs and tumor cells played a
role in the CRC microenvironment. To explore a candi-
date that functions between MSCs and CRC cells, con-
ditioned media from the cultured human MSCs were
screened for various chemokines using a chemokine array
kit. Of note, several chemokines were produced by MSCs
at a relatively high level, and, especially, CCL3, CCL4, and
CCL5 were highly detected (Fig. 1a). We also conﬁrmed
the expressions of these chemokines at mRNA levels by
quantitative reverse transcription-PCR (qRT-PCR; data
not shown). Because the cognate receptor for these che-
mokines is CCR5, we speculated that CCL3/4/5–CCR5
axis could function between MSCs and CRC cells.
Next, we examined the expression of CCR5 in several
CRC cell lines by ﬂow cytometry, and found that these
cells slightly expressed CCR5 on the cell surface (Fig. 1b,
top). However, when cell membrane was permeabilized, a
relatively strong CCR5 expression could be detected
within the cytoplasm (Fig. 1b, bottom).
To investigate the functional consequences of the
interaction between MSCs and CRC cells, we employed
the co-inoculation mice model in which CRC cells (1 ×
106 cells) were mixed with BM-derived human MSCs (1 ×
106 cells) and injected subcutaneously into immuno-
compromised mice (Fig. 1c). The growth kinetics of the
MSC-mixed tumors (CRC cells+MSCs) in mice were
compared to those injected with CRC cells alone. We
tested three CRC cell lines (i.e., HT29, SW480, and
HCT116), and found that the mixture of MSCs sig-
niﬁcantly accelerated tumor growth in vivo in all cell lines
(Fig. 1d). Mice injected with HT29+MSCs displayed the
signiﬁcantly larger tumors compared to those injected
with HT29 alone. Mice injected with SW480+MSCs or
HCT116+MSCs displayed the visible tumors, whereas
mice injected with SW480 or HCT116 alone did not
exhibit tumor engraftment.
CCR5-mediated cellular responses of CRC cell lines
To investigate the role of CCR5 in CRC progression, we
established stable HCT116 transfected lines in which
CCR5 or empty vector was introduced by retroviral
transfection (referred as HCT116-CCR5 or HCT116-EV
cells, respectively). We conﬁrmed that the mRNA and
protein levels of CCR5 were markedly higher in HCT116-
CCR5 cells compared to the control cells (HCT116-EV
cells) (Fig. 2a, b). To examine the intracellular signaling
pathways via CCR5, we analyzed the phosphorylation of
Erk, PI3K, and Akt after treatment with CCL5 (Fig. 2c).
Upon exposure of HCT116-CCR5 cells to CCL5, there
was notable phosphorylation of Erk, PI3K, and Akt. On
the other hand, in HCT116-EV cells, CCL5 stimulation
caused only the phosphorylation of PI3K, while it did not
increase the phosphorylation of Erk and Akt. Next, to
explore the CCR5-mediated cellular function, we analyzed
the effect of CCL5 on cell proliferation, and found that
CCL5 signiﬁcantly enhanced the proliferation of both
HCT116-EV and HCT116-CCR5 cells (Fig. 2d). The
proliferation rates of HCT116-CCR5 cells with or without
CCL5 were almost similar to those of HCT116-EV cells,
indicating the overexpressed CCR5 did not confer any
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Fig. 1 (See legend on next page.)
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proliferative advantage. Furthermore, we performed an
in vitro chemotaxis assay to investigate whether the che-
mokine axis via CCR5 could induce cell migration. As
expected, CCL5 caused directional migration in HCT116-
CCR5 cells, whereas it did not in HCT116-EV cells
(Fig. 2e).
MSC promotes CRC tumor growth in vivo via CCR5
To assess the effect of CCR5 on the tumor growth
in vivo, we inoculated HCT116-EV or HCT116-CCR5
cells (4 × 106 cells) into immunocompromised mice and
found that there was no signiﬁcant difference in size
between the two cells (Supplementary Fig. 1). Next, to
examine the effect of MSC mixture, we employed the co-
inoculation mice model in which HCT116-EV or
HCT116-CCR5 cells (1 × 106 cells) were mixed with
MSCs (1 × 106 cells), and then inoculated subcutaneously
into the mice (Fig. 3a). The size of the tumors in mice
injected with HCT116-CCR5+MSCs was much larger
compared to that in mice injected with HCT116-EV+
MSCs (Fig. 3b, c). Three weeks after inoculations, we
conﬁrmed that CCR5 protein continued to be expressed
in the HCT116-CCR5+MSCs tumors, and that the
pathological ﬁndings of the transplanted tumors were
similar between the two cells (Fig. 3c). There were a few
alpha-smooth muscle actin (α-SMA)-positive cells within
these tumors.
To additionally verify the roles of CCR5, we attempted
to suppress tumor growth with a CCR5 inhibitor, mar-
aviroc. Seven days after inoculation, we started to inject
maraviroc (30 mg/kg/day) repeatedly into the mice, and
then compared the effect to the control vehicle up to
3 weeks after inoculation. In the HCT116-EV+MSCs
tumors, there was no signiﬁcant difference in size between
the two groups (P= 0.37). On the other hand, in the
HCT116-CCR5+MSCs tumors, maraviroc signiﬁcantly
reduced tumor size (P= 0.042). These results suggest that
CCR5 signaling is important for the interaction between
CRC cells and MSCs, and that an inhibitor of CCR5 could
suppress CRC progression.
CCR5 expression in primary CRC and preoperative serum
CCL3/4 levels are correlated with patients’ prognosis
To evaluate the clinical relevance of the above-
mentioned results, we examined CCR5 expression in CRC
cells with 89 clinical specimens by immunohistochemical
analysis. We found that 20 cases (20/89; 29%) had high
levels of CCR5, whereas 69 cases (69/89; 71%) had com-
paratively lower levels (Fig. 4a). CCR5 expression was not
associated with sex, age, tumor location, T-factor, N-
factor, and M-factor (Table 1). To evaluate the effect of
patients’ prognosis, we analyzed the overall survival (OS),
cancer-speciﬁc survival (CSS), and relapse-free survival
(RFS). Statistical analyses indicated that stages 0–IV
patients with CCR5-high CRCs tended to exhibit shorter
OS and CSS than those with CCR5-low CRCs (P= 0.08
and 0.07, respectively), although the difference was not
signiﬁcant (Fig. 4b). Furthermore, we performed subgroup
analyses based on the stage-based classiﬁcation, and
found that stage III/IV patients with CCR5-high CRCs
exhibited a signiﬁcantly poorer prognosis (OS, CSS, and
RFS) than those with CCR5-low CRCs (P= 0.001, 0.009,
and 0.035, respectively; Fig. 4c). On the other hand, such a
correlation was not observed in the analyses on stage 0/I/
II patients. These results highlight the clinical importance
of CCR5 expression in CRC, especially at advanced stages.
Serum levels of CCL3, CCL4, and CCL5 have been
recently reported to be useful as biomarkers of several
cancers16–21. Therefore, we investigated whether they
could be used as biomarkers of CRC progression. We
measured the preoperative serum levels of CCL3, CCL4,
and CCL5 from 114 CRC patients by enzyme-linked
immunosorbent assay (ELISA) (Table 2). To evaluate the
clinical outcome, we analyzed the OS, CSS, and RFS.
Statistical analysis indicated that the cases with high
CCL3 levels exhibited a signiﬁcantly shorter OS and CSS
compared to those with low CCL3 levels (P= 0.02 and
0.02, respectively), although such a correlation was not
observed in RFS (Fig. 5a). The cases with high CCL4 levels
exhibited a signiﬁcantly shorter OS compared to those
with low CCL4 levels (P= 0.04), and a similar correlation
was also observed in CSS and RFS (P= 0.06 and 0.07,
respectively) (Fig. 5b). On the other hand, there was no
association between the CCL5 concentration and prog-
nosis (Fig. 5c).
Discussion
MSCs have the multilineage differentiation potential
and the capacity to home into the damaged tissues and
modulate immune responses. Because of these properties,
(see ﬁgure on previous page)
Fig. 1 Relationship between colorectal cancer (CRC) cells and mesenchymal stem cells (MSCs). a Chemokine array using supernatants
collected from MSCs. Array membrane (left) and relative intensity values of each chemokine (right). A positive control was set as 100. b Cell surface
expression (top) and intracellular expression (bottom) of C-C chemokine receptor type 5 (CCR5) analyzed by ﬂow cytometry. Red area represented
isotype IgG control and blue area did anti-CCR5 Ab. c Schema of co-inoculation mice model. d Xenograft growth curves of SW480 (letf), HT29
(middle), and HCT116 (ritght) injected with or without MSCs. Mean; bar, ±SE, n= 4 (SW480), n= 6 (HT29 and HCT116) (Student’s t test; *P < 0.01,
**P= 0.03)
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Fig. 2 (See legend on next page.)
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the therapeutic value of MSCs has been investigated in
various diseases including regenerative medicine5,22,23.
However, some studies have reported the risk of potential
tumorigenicity related to the MSC-based therapy through
genetic instability and transformation after prolonged cell
culture23–25. Although there are not enough data/studies
to draw a conclusion about the risk of tumorigenicity in
the MSC-based therapy, the development of long-term
follow-up in clinical settings is encouraged. Tumor-
promoting effect of MSCs have been reported in various
types of cancer, including CRC26–30. Recently, Chen et al.
reported that CCL5 secreted by tumor necrosis factor-α-
primed MSCs could promote tumor development via
CCR1 expressed on CRC cells, which results in
epithelial–mesenchymal transition via β-catenin/Slug
pathway29. CCL5 is one of the C-C chemokines secreted
from various cell types and interacts with CCR1, CCR3,
and CCR531. The CCL5–CCR5 axis has been reported to
promote tumor progression by several lines of evi-
dence7,32–35. Karnoub et al. showed the essential role
played by CCL5–CCR5 axis in breast cancer metastasis to
lungs7. Velasco-Velazquez et al. showed that
CCL5–CCR5 axis was preferentially activated in more
malignant subtype of breast cancer, and that a CCR5
inhibitor, maraviroc, reduced the progression of CCR5+
breast cancer cells in vitro and in vivo35. In CRC, one
report showed that CCL5/CCR5 expression was upregu-
lated in primary and metastatic CRC36, whereas another
report showed that low CCR5 expression was correlated
with advanced stages and reduced CD8+ T-cell inﬁltra-
tion37, indicating that the role of CCR5 in CRC is still
controversial. Recently, Halama et al. reported that CCL5
produced by T lymphocytes in CRC liver metastases has
tumor-promoting effects on tumor cells and tumor-
associated macrophages (TAMs), and that the CCR5
inhibitor, maraviroc, led to tumor reduction through
repolarization of TAMs38. CCL3–CCR5 axis has pro-
tumorigenic effects on oral squamous cell carcinoma39,
and lung metastasis40. Tanabe et al. reported that cancer-
associated ﬁbroblasts (CAFs) accumulated into tumor
sites via CCL3–CCR5 axis, and that CCR5 blockage with
maraviroc could suppress tumor growth in a mouse
colitis-associated CRC model41. Sasaki et al. reported that
CCL4–CCR5 axis could contribute to bone metastasis of
breast cancer; cancer cell-derived CCL4 could induce
CCR5-exrpressing ﬁbroblasts to support tumor
progression42.
CCR5 is expressed in several types of cancer cells as well
as immune cells, T lymphocytes, dendritic cells, leuko-
cytes, and stromal cells43. Only a few studies have inves-
tigated the relationship between CCR5 expression and
patients’ prognosis44–47. In the present study, CCR5
expression was correlated with poor prognosis of CRC
patients, especially those at more advanced stages (stage
III/IV) (Fig. 4c). Thus, we speculate that the chemokine
axis via CCR5 might be one of the critical axes for tumor
progression in advanced stages.
CAFs have been known to contribute to cancer pro-
gression48–50. Resident ﬁbroblasts, smooth muscle cells,
endothelial cells, and epithelial cells are assumed to be the
sources of CAFs in the TME. Recently, some researchers
reported that MSC is a potent source of CAFs. For
example, Worthley et al. reported that CAFs in gastric
cancer and rectal cancer of female patients who received
BM transplants from male donors were positive for Y-
chromosome marker derived from a male BM donor,
which suggests that the CAFs are derived from BM13.
Using mouse models of inﬂammation-induced gastric
dysplasia, Quante et al. showed that at least 20% of CAFs
were originated from MSCs present in the BM, and that
CAFs were recruited to the tumor in a transforming
growth factor-β-dependent manner together with the
CXCL12–CXCR4 axis14. Jung et al. reported that
CXCL16 secreted from prostate cancer facilitates con-
version of MSCs into CAFs11. In the present study, we
found that scattered spindle-shaped cells like ﬁbroblasts
in the xenograft co-inoculated with MSC, and that a few
of them were αSMA-positive (Fig. 3c), which might
delineate that some of co-inoculated MSCs could differ-
entiate to αSMA-positive stromal cells like CAFs.
Although MSCs have important roles in the development
of TME, their mechanism of action remains to be
elucidated.
As for the serum CCR5 ligands (i.e., CCL3, CCL4, and
CCL5), serum levels of CCL3 and CCL4 were signiﬁcantly
correlated with patients’ OS in diffuse large B-cell lym-
phoma16. In chronic lymphocytic leukemia, serum levels
of CCL3 and CCL4 were elevated17, and high CCL3 levels
(see ﬁgure on previous page)
Fig. 2 C-C chemokine receptor type 5 (CCR5)-mediated cellular responses in vitro. a CCR5 mRNA expression in HCT116 transfectant cells
quantiﬁed by quantitative reverse transcription-PCR. Means; bar, ±SD, n= 3. b CCR5 cell surface expression (top) and intracellular expression (bottom)
analyzed by ﬂow cytometry. c Intracellular signaling of HCT116 transfectant cells treated with C-C motif chemokine ligand 5 (CCL5; 100 ng/ml). d Cell
proliferation assay using Cell Counting Kit-8 assay. HCT116 transfectant cells treated with CCL5 (100 ng/ml) analyzed at day 0, 3, and 6. Normalize an
absorbance at day 0 as 1. Mean; bars, ±SD, n= 3 (Student’s t test; *P= 0.008, **P= 0.03). e Chemotaxis index of HCT116 transfectant cells treated with
various CCL5 concentrations (left). Mean; bars, ±SD, n= 6 (Student’s t test; *P < 0.001). Representative images of transwell membrane (right). Scale bar,
200 μm
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could be a predictor of poorer prognosis18. In oral squa-
mous cell carcinoma, high serum CCL4 levels were
associated with a more advanced stage19. High serum
CCL4 levels were also reported to be associated with a
poor OS in lung adenocarcinoma20. Recently, serum levels
















































































































Fig. 3 Enhancement of tumor-promoting effect of mesenchymal stem cells (MSCs) by C-C chemokine receptor type 5 (CCR5) axis. a
Schema of co-inoculation mice model. HCT116 transfectant cells were mixed with MSCs. b Xenograft growth curves of HCT116-EV and HCT116-CCR5
with MSCs. Mean; bar, ±SE, n= 6 (Student’s t test; *P= 0.01). c Images of xenograft appearance at day 21 (left). Histological ﬁndings of xenograft
(right). Hematoxylin and eosin (HE) and immunohistochemical staining for αSMA and anti-CCR5. Scale bar, 200 μm. d Schema of treatment schedule.
e Xenograft growth curves of HCT116-EV (left) and HCT116-CCR5 (right) with MSCs. Dotted lines show treatment group with maraviroc 30 mg/kg/
day, and solid lines show control group with vehicle. Means; bars, ± SE, n= 6 each group (Student‘s t test, *P= 0.042)
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reported to be sensitive predictors for the presence of
hepatocellular carcinoma21. To our knowledge, the asso-
ciation of CRC with serum levels of CCL3, CCL4, and
CCL5 has not been reported so far. Thus, our study is the
ﬁrst to evaluate this association.
The human immunodeﬁciency virus (HIV) utilizes
CCR5 as a co-receptor with CD4 to enter target cells;
therefore, the CCR5 has been heavily evaluated as an
important treatment target of HIV-1 infection43.
Repurposing the drugs already approved as non-
anticancer drugs is an attractive strategy because of
the cost, safety, and clinical validation of protocols51. In
this context, CCR5 is one of the attractive targets for
cancers, because it has been already used as a target for
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Fig. 4 Correlation of C-C chemokine receptor type 5 (CCR5) expression in primary tumor with colorectal cancer (CRC) patients’ prognosis.
a Immunohistochemical staining for CCR5 in primary CRC. Representative images are shown (scale bars, 500 μm). Magniﬁed images were shown at
right upper quadrant (scale bars, 50 μm). b Survival curves estimated by Kaplan-Meier method in all patients. Overall survival (OS: left), cancer-speciﬁc
survival (CSS: middle), and recurrence-free survival (RFS: right) were shown. P value calculated by log-rank test. c Survival curves in subgroups divided
into early stages (stage 0/I/II: top) and advanced stages (stage III/IV: bottom). P value calculated by log-rank test
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inhibition of HIV entry52,53. Maraviroc is approved by U.
S. Food and Drug Administration, and commonly used
for treatment of HIV infection. A new CCR5 antagonist
in advanced clinical trials for treatment of HIV infection
is cenicriviroc (TAK-652), which is a second-generation
small-molecule CCR5 antagonist and dual chemokine
receptors inhibitor for CCR2 and CCR554. Development
of another dual chemokine-based agent (CCR5/CXCR4)
is in now ongoing53. As for cancer treatments, various
CCR5 antagonists, including maraviroc, vicriviroc,
TAK-779, Met-CCL5, and anibamine, have been shown
to have antitumor effect in preclinical mouse models34.
Among them, maraviroc has been most intensively
investigated in various mouse models.
In this report, we have shown that CCL3/4/5–CCR5
axis facilitates tumor progression by the interaction
between MSCs and CRC cells. These results suggested
that some chemokines secreted from MSCs could be
important factors among the interaction between MSCs
and cancer cells in the TME. Our ﬁndings that α-CCR5
treatment blocked the MSC-induced tumor progression
suggest that the inhibition of MSC–CRC interaction
could represent an effective treatment strategy for CRC
and underscore the need for clinical trials of these
drugs.
Table 2 Patients and tumor characteristics of analyzed
serum sample from another cohort of 114 patients
Characteristics No. of patients
Age, years
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Table 1 Univariate analysis of patients and tumor
characteristics with expression of CCR5
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Materials and methods
Cell lines and reagents
SW480, SW620, HT29, HCT116, and DLD1 human CRC
cells were supplied from American Type Culture Collection
and were maintained in low-glucose Dulbecco’s modiﬁed
Eagle’s medium (DMEM; Nacalai Tesque, Kyoto, Japan)
containing 10% fetal bovine serum and 1% penicillin/strep-
tomycin mixture. Human BM-derived MSCs were supplied
from Lonza (PT-2501; Basel, Switzerland) and cultured with
MSCGM BulletKit (PT-3001; Lonza). We used them for
experiments by passage 5 according to the manufacturer’s
protocol. Recombinant human CCL5/RANTES protein was
obtained by R&D systems (Minneapolis, MN, USA). An
antagonist of the CCR5, maraviroc, was purchased from
Cayman Chemical (Ann Arbor, MI, USA).
Chemokine array
Human chemokine antibody array was obtained from
RayBiotech (Norcross, GA, USA). After MSCs were cultured
for 48 h, the supernatant was collected and then analyzed by
human chemokine antibody array kit (RayBiotech), according
to the manufacturer’s protocol. The signal intensity of each
chemokine spot was measured by a LAS-3000 mini lumino
image analyzer (Fjiﬁlms, Tokyo, Japan). After substrate
negative control value, relative pixel density value was cal-
culated with the positive control as 100.
Flow cytometry
CRC cells at subconﬂuency (50–70%) were detached
with 2 mM EDTA in phosphate-buffered saline (PBS).
After washes, 5 × 105 CRC cells were incubated on ice
for 30 min with anti-human CCR5 antibody (mono-
clonal mouse IgG2b clone #45531; R&D Systems).
After washing, they were incubated with
allophycocyanin-conjugated anti-mouse secondary
antibodies (Cat # 405308, BioLgend, San Diego, CA,
USA) and analyzed on a BD Accuri C6 ﬂow cytometer
(BD Biosciences, San Jose, CA, USA). To evaluate
CCR5 intracellular expression, cells were permalized
with BD Cytoﬁx/Cytoperm Fixation/Permeabilization
P = 0.06P = 0.04 P = 0.07
P = 0.55 P = 0.71 P = 0.97








































































































































































































Fig. 5 Correlation of preoperative serum levels of C-C motif chemokine ligand 3 (CCL3), C-C motif chemokine ligand 4 (CCL4), and C-C
motif chemokine ligand 5 (CCL5) with colorectal cancer patients’ prognosis. a–c Survival curves of overall survival (OS), cancer-speciﬁc survival
(CSS), and relapse-free survival (RFS) estimated by Kaplan-Meier method in CCL3 (a), CCL4 (b), and CCL5 (c). The median number of CCL3, CCL4, and
CCL5 (i.e., 26.0, 21.0, and 24,900 pg/ml, respectively) was used as cutoff value. P value was calculated by log-rank test
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Kit (BD Biosciences) according to the manufacturer’s
protocol.
Retroviral transduction of HCT116 human colon cancer cell
Human CCR5 cDNA was obtained from peripheral
blood mononuclear cell of healthy donor and ampliﬁed by
RT-PCR. The following primers were used, with each
containing either a NotI or BamHI site. 5′-CCGGCGG
CCGCGCCACCATGGATTATCAAGTGTCAAG-3′ and
5′-CCGGGATCCTCACAAGCCCACAGATATTT-3′.
The obtained PCR fragment was digested with NotI and
BamHI, and subcloned into retroviral vector pHIV-
ZsGreen (from Hisamori S, Kyoto University). The
resulting vector was conﬁrmed by sequencing to coin-
cident with the published data (GenBank Accession No.
NM_000579). Using lentiviral packaging plasmid psPAX2
and VSV-G envelope expressing plasmid pMD2.G,
HCT116 CRC cells were transfected pHIV-CCR5-IRES-
ZsGreen with produced lentivirus. After initial transfec-
tion, the high expressed ZsGreen cells were isolated using
BD FACSAria II cell sorter (BD Biosciences).
qRT-PCR analyses
Total RNA was extracted and reverse transcription was
performed with RevaTra Ace (TYOBO, Osaka, Japan)
according to the manufacturer’s protocol. The synthe-
sized cDNA was quantiﬁed with StepOnePlus Real-Time
PCR system (Thermo Fisher Scientiﬁc, Waltham, MA,
USA) and THUNDERBIRD SYBR qPCR Mix (TOYOBO).





Cells were lysed with SDS sample buffer (70 mM Tris-
HCl, 3% SDS, and 10% glycerol) with inhibitor cocktails
of protease and phosphatase. Primary antibodies were
rabbit monoclonal anti-phospho-p44/42 kinase
(Thr202/Tyr204: Cell Signaling Technology, Danvers,
MA, USA), anti-p44/42 kinase (Cell Signaling Tech-
nology), rabbit monoclonal anti-phospho-Akt (Ser473:
Cell Signaling Technology), rabbit monoclonal anti-Akt
(Cell Signaling Technology), rabbit polyclonal anti-
phospho-p70 S6 kinase (Thr389: Cell Signaling Tech-
nology), rabbit polyclonal anti-p70 S6 kinase (Cell Sig-
naling Technology), and mouse monoclonal anti-β-
actin-peroxidase (Sigma-Aldrich, St. Louis, MO, USA).
For stimulation experiments, cells were starved for 24 h
with serum-free DMEM and then stimulated with 100
ng/ml of CCL5. Cell lysates were obtained after the
indicated times stimulation and subjected to SDS-
polyacrylamide gel electrophoresis, immunoblotted
with the primary antibodies followed by horseradish
peroxidase-conjugated secondary antibodies, and then
analyzed by a lumino image analyzer.
Cell proliferation assay
Cell proliferation was assayed with Cell Counting Kit-8
(Dojin, Kumamoto, Japan) according to the manu-
facturer’s protocol. Cells were cultured at a density of
2000 cells/well of 96-well plate in serum-free media with
or without chemokine ligand CCL5. Each sample were
analyzed absorbance at day 0, 3, and 6, and calculated
relative rate with day 0 value as 1.
Chemotaxis assay
Migration assay was assayed in 24-well Transwell cell
culture chambers (8 μm-pore membrane) (Corning, NY,
USA). Membrane were precoated with 5 μg of ﬁbronectin
in a volume of 50 μl on the lower surface, dried, and
washed before use. After 24 h starvation with serum-free
DMEM, HCT116-EV or CCR5-OE cells (2 × 104 cells/
well) were added to the upper chamber and serum-free
media with indicated ligand concentration was added to
the lower chamber. After 6 h incubation, cells attached on
the lower surface of the membrane were counted in at
least ﬁve different ﬁelds (original magniﬁcation × 200).
Animal tumor model
Eight- to 11-week-old female KSN/slc nude mice (Japan
SLC, Hamamatsu, Japan) were bred under speciﬁc
pathogen-free conditions. Protocols of animal assay were
approved by the Animal Experiment Committee of the
University of Kyoto. For assessment of the role of coex-
isted MSC, the mice were divided into two group, and 1 ×
106 CRC cells alone or both 1 × 106 CRC cells and 1 × 106
MSCs in 100 μl PBS were subcutaneously injected into the
ﬂanks of each mouse. To examine maraviroc inhibitory
effect on interaction between CRC and MSCs, HCT116-
EV and HCT116-CCR5 cells were co-inoculated with
MSCs in the same manner and the mice were randomized
in control group (vehicle, 100 μl PBS with 5% dimethyl
sulfoxide, intraperitoneal (i.p.)) and treatment group
(maraviroc 30 mg/kg, i.p.). Treatment was started at day 7
after cell inoculation and continued for 14 days. Tumor
volumes were calculated using the formula (length ×
width2) × 0.5.
Immunohistochemistry
Formalin-ﬁxed, parafﬁn-embedded sections were
stained with anti-human CCR5 antibody (anti-human
CCR5 antibody: monoclonal mouse IgG2b clone # 45523,
dilution 1:50) (R&D) by the avidin-biotin immunoperox-
idase method. Antigen retrieval was conducted in citrate
buffer (pH: 6.0) at sub-boiling temperature for 10min.
The primary antibodies were applied and incubated over
night at 4 °C. For primary CRC tissue, the expression of
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CCR5 was classiﬁed into three groups based on the
expression intensity: −, absent; +, positive (almost cyto-
plasmic staining); ++, strong positive (membranous
staining) and was deﬁned to be high expression if the
tumors possessed strong positively stained (++) cells and
to be low expression if positively stained or absent. The
slides were evaluated without prior knowledge of other
data.
Enzyme-linked immunosorbent assay
Serum protein levels of CCL3, CCL4, and CCL5 were
measured with Human CCL3, CCL4, and CCL5 DuoSet
ELISA (R&D), according to the manufacturer’s protocol.
The serum protein levels of CCL3, CCL4, and CCL5 were
divided into high group and low group. Median vale was
used as cutoff value.
Patients and clinicopathological data
A total 89 of resected CRC samples were collected at
Kyoto University Hospital in 2008. For the analysis of
serum CCL3, CCL4, and CCL5 levels, preoperative
serum samples were collected from 114 CRC patients
between 2011 and 2014. These study protocols were
approved by the Institutional Review Board of Kyoto
University, and the patients provided their consents for
data analysis.
Statistical analysis
Analyzed values were expressed as means ± standard
deviation in in vitro experiments and means ± standard
error in in vivo experiments. Categorical data were
determined with Fisher’s exact test. Continuous variables
were determined with Student’s t test. The log-rank test
was used for analysis of OS, CSS, and RFS. All analyses
were two-sided, and P value < 0.05 was considered as
statistically signiﬁcant. Statistical analyses were performed
using JMP Pro software, version 14.0.0 (SAS Institute Inc,
Cary, NC, USA).
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